Pharmaceutical Executive December 12, 2024
Mike Hollan

The industry is facing an uncertain regulatory landscape in the coming year.

The recent election of Donald Trump as president of the United States is sure to have a significant impact on many industries, including the pharmaceutical and life sciences industries. Whether its actions that will have a direct impact, such as naming Robert F. Kennedy Jr to be head of the Department of Health and Human Services, or indirect impacts, such as his plans to place tariffs on certain goods, the industry is preparing for an uncertain regulatory landscape. Arthur Wong, health care managing director at S&P Global Rankings, spoke with Pharmaceutical Executive about the potential impacts of the election.

Pharmaceutical Executive: How will the expiration of ACA subsidies...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Interview / Q&A, Pharma, Pharma / Biotech, Trends
At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected
NIH's unfinished business
Arcadia Launches AI-Powered Precision Medicine Solution
AbbVie to write off $3.5B over failed schizophrenia drug
Drug Price Negotiation Requires Oversight To Protect Older Americans

Share This Article